Efficacy, safety, and cost of new anticancer drugs.
作者信息
Garattini Silvio, Bertele Vittorio
机构信息
Mario Negri Institute for Pharmacological Research, 20157 Milan, Italy.
出版信息
BMJ. 2002 Aug 3;325(7358):269-71. doi: 10.1136/bmj.325.7358.269.
Abstract
摘要
相似文献
1
Efficacy, safety, and cost of new anticancer drugs.
BMJ. 2002 Aug 3;325(7358):269-71. doi: 10.1136/bmj.325.7358.269.
2
Oncology drugs enter the US market faster than in Europe but cost more.
JAMA. 2012 Aug 8;308(6):555. doi: 10.1001/jama.2012.9535.
3
Approvals in 2016: cost-benefit challenges of new anticancer agents.
Nat Rev Clin Oncol. 2017 Feb 20;14(3):133-134. doi: 10.1038/nrclinonc.2017.12.
4
Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx173.
5
Cancer drugs: high price, uncertain value.
BMJ. 2017 Oct 4;359:j4543. doi: 10.1136/bmj.j4543.
6
Rising Cost of Anticancer Medications in the United States.
Ann Pharmacother. 2017 Aug;51(8):706-710. doi: 10.1177/1060028017702406. Epub 2017 Mar 24.
7
Approvals in 2016: questioning the clinical benefit of anticancer therapies.
Nat Rev Clin Oncol. 2017 Feb 20;14(3):135-136. doi: 10.1038/nrclinonc.2017.18.
8
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
J Clin Oncol. 2011 Jun 20;29(18):2543-9. doi: 10.1200/JCO.2011.35.2393. Epub 2011 May 23.
9
Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified.
BMJ. 2002 Nov 30;325(7375):1302; author reply 1302. doi: 10.1136/bmj.325.7375.1302/a.
10
Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs.
J Oncol Pract. 2017 Jul;13(7):e653-e665. doi: 10.1200/JOP.2016.020339. Epub 2017 May 11.
引用本文的文献
1
1-Pyrazolo[3,4-]quinolines: Synthesis and Properties over 100 Years of Research.
Molecules. 2022 Apr 26;27(9):2775. doi: 10.3390/molecules27092775.
2
Enhanced Proapoptotic Effects of Water Dispersed Complexes of 4-Thiazolidinone-Based Chemotherapeutics with a PEG-Containing Polymeric Nanocarrier.
Nanoscale Res Lett. 2019 Apr 23;14(1):140. doi: 10.1186/s11671-019-2945-7.
3
Patients not patents: Drug research and development as a public enterprise.
Eur J Clin Invest. 2018 Feb;48(2). doi: 10.1111/eci.12875. Epub 2018 Jan 5.
4
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.
BMJ. 2017 Oct 4;359:j4530. doi: 10.1136/bmj.j4530.
5
Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future.
Front Pharmacol. 2017 Apr 4;8:171. doi: 10.3389/fphar.2017.00171. eCollection 2017.
6
Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.
PLoS One. 2017 Apr 12;12(4):e0175409. doi: 10.1371/journal.pone.0175409. eCollection 2017.
7
Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology Drugs.
Front Pharmacol. 2016 Jun 1;7:144. doi: 10.3389/fphar.2016.00144. eCollection 2016.
8
Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study.
CMAJ Open. 2015 Jul 17;3(3):E286-91. doi: 10.9778/cmajo.20150023. eCollection 2015 Jul-Sep.
9
Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?
Soc Sci Med. 2015 Apr;131:207-14. doi: 10.1016/j.socscimed.2014.12.007. Epub 2014 Dec 2.
10
Market-access agreements for anti-cancer drugs.
J R Soc Med. 2015 May;108(5):166-70. doi: 10.1177/0141076814559626. Epub 2014 Dec 8.
本文引用的文献
1
Adjusting Europe's drug regulation to public health needs.
Lancet. 2001 Jul 7;358(9275):64-7. doi: 10.1016/s0140-6736(00)05258-2.
2
Opinion: why the variation in breast cancer survival in Europe?
Breast Cancer Res. 1999;1(1):22-6. doi: 10.1186/bcr8. Epub 1999 Oct 7.
3
Antibody-targeted immunotherapy for treatment of malignancy.
Annu Rev Med. 2001;52:125-45. doi: 10.1146/annurev.med.52.1.125.
4
The decline in cancer mortality in the European Union, 1988-1996.
Eur J Cancer. 2000 Oct;36(15):1965-8. doi: 10.1016/s0959-8049(00)00283-5.
5
Temozolomide for malignant brain tumours.
Lancet. 2000 Apr 1;355(9210):1115-6. doi: 10.1016/S0140-6736(00)02055-9.
6
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
JAMA. 1999 Oct 20;282(15):1453-7. doi: 10.1001/jama.282.15.1453.
7
8
Introduction: the EUROCARE II Study.
Eur J Cancer. 1998 Dec;34(14 Spec No):2139-53. doi: 10.1016/s0959-8049(98)00334-7.
9
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet. 1998 Sep 19;352(9132):930-42.
10
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet. 1998 May 16;351(9114):1451-67.
Zotero 插件